The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

In preclinical drug development, choosing the right biological model is the most critical initial decision. Selecting an inappropriate model, such as the wrong PDX or organoid line, guarantees the research program will fail as it will be designed to answer the wrong question from the outset.

Traditional 2D cell cultures can be misleading. Advanced 3D models, by reconstituting the tumor microenvironment with stromal cells, can uncover mechanisms of drug resistance (e.g., to ADCs) that are completely invisible in simpler systems, providing more clinically relevant data.

Only 5% of investigational cancer drugs reach the market due to the gap between lab models and human biology. Dr. Saav Solanki highlights organoids, which use real patient tissue, as a key translational model to improve the predictive accuracy of preclinical research and increase the low success rate.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

Treating 'non-clear cell' kidney cancer as a single entity is a major research limitation. Experts argue that distinct histologies like papillary and chromophobe are different diseases. Future progress requires dedicated, international trials for each subtype rather than grouping them due to rarity.

Current immunocompetent mouse models for RCC have a major limitation: they are naturally T-cell depleted, with T-cells comprising only 1-10% of immune cells versus 40-70% in human tumors. This makes them excellent for studying myeloid biology but suboptimal for understanding T-cell mediated responses to immunotherapy.

A major cause of clinical trial failure is that preclinical testing uses immortalized cancer cell lines cultured for decades. These cells have abnormal genomes and gene expressions that don't represent actual tumors, creating a massive translational gap that Noetik's patient-derived data aims to solve.

Unlike cell-line derived (CDX) models, PDX models are grown directly from patient samples without a culture phase. This preserves the original tumor's heterogeneity, leading to more clinically relevant and predictive data in preclinical radiopharmaceutical studies.